UBS downgrades First Horizon stock rating on limited upside

UBS downgraded First Horizon (FHN) to Neutral from Buy and cut its price target to $25 from $29, noting limited upside absent M&A and forecasting fiscal 2026/2027 EPS estimates 1%–4% below consensus. The stock trades at a P/E of 12.45 and PEG of 0.31, with InvestingPro flagging FHN as overvalued relative to fair value and fiscal 2026 EPS forecast of $2.12. Corporate actions include redemption of 6.600% Series C preferred on May 1, 2026 at $25 per depositary share (equivalent to $10,000 per Series C share), sale of 16M depositary shares of Series H, and a 13% quarterly dividend increase to $0.17 payable April 1, 2026; management added two senior hires. Overall, UBS sees upside constrained and warns the market premium could be at risk if the company becomes an acquirer.

Analysis

The market appears to be pricing out M&A optionality from a regional bank that previously carried a takeover premium; when optionality is removed, P/E compression can happen quickly because investor willingness to pay for multiple expansion relies on a clear path to scale or a takeover payoff. Management moves into fee-generating businesses and active capital reshuffles are typical stabilizers, but they take 12–24 months to materially re-rate earnings quality and may temporarily compress ROE as capital is recycled into lower-leverage, fee-based assets.

A likely second-order pressure is on regional deposit economics: if this bank pivots to being an acquirer rather than an obvious takeover target, competing banks in the same franchise footprint face both slower consolidation-driven deposit repricing and potential deposit outflows as customers seek scale and stability — that dynamic favors larger wealth managers and national banks with deposit diversification. On the liability side, rolling perpetual-like instruments and layering new capital creates reflexive event-risk windows where funding, not fundamentals, drives intraday volatility; volatility spikes around capital events are a preferred hedge-fund hunting ground.

The practical corollary is timing: shareholder re-rating risk is front-loaded (weeks–months around capital or M&A signals) while earnings-quality improvement is back-loaded (quarters–years). That asymmetry implies short-dated protection and pair trades hedged by larger, fee-rich franchises will outperform blunt buy-and-hold exposures until the company demonstrates sustained fee revenue growth or a credible M&A strategy.

Key Decisions for Investors

• Buy protection: Purchase a 3–6 month put spread on FHN sized to 2–4% of portfolio (buy 25–30 delta put, sell 10–15 delta put) to limit premium outlay. Rationale: protects against near-term P/E de-rating around capital/M&A signals; max loss = premium (~2–4% allocation), target payoff >3x if shares re-rate downward.
• Pair trade: Short FHN equity vs. long Morgan Stanley (MS) for 6–12 months, equal dollar notional. Rationale: hedges market/systemic beta while isolating re-rating risk; if FHN’s premium collapses while fee-rich MS benefits from wealth flows, expect positive spread capture. Risk: macro shock that hits wealth AUM will hurt MS; size accordingly.
• Event play: Scale into incremental short exposure ahead of any announced capital events or shareholder meetings (tighten stops after announcements). Time horizon: days–weeks. Rationale: capital transactions historically create 10–20% short-term implied-volatility and price moves; trade with disciplined stop-loss to avoid execution risk.
• Contrarian tactical long (small): If 12–24 month view is constructive on fee diversification, buy out-of-the-money 12–18 month call options (or 2–3% equity position) as a low-cost punt. Rationale: captures asymmetric upside if management successfully converts fee growth into a sustained multiple expansion; downside limited to premium or small equity stake.